MDS 2023
Aug 27 - 31, 2023 | Copenhagen, Denmark
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
Development of Potent, Orally Bioavailable, and Highly Selective LRRK2 PROTAC® Degrader Molecules as Potential Disease Modifying Therapeutics for Parkinson’s DiseaseK Kelly et al.
Poster
LRRK2 PROTAC® Degrader Molecules Induce Robust Biomarker Responses in Preclinical In Vivo Pharmacology Studies Following Acute and Chronic Oral DosingJ Meredith Jr. et al.